MAP2K7 and cancer: The NCI Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT) clinical trial (NCT01827384) assessed the utility of applying tumor DNA sequencing to treatment selection by comparing the efficacy of 4 study regimens: the PARP inhibitor veliparib with the alkylating agent temozolomide, or the WEE1 tyrosine kinase inhibitor adavosertib plus the alkylating agent carboplatin (targeting the DNA repair pathway); the mTOR inhibitor everolimus (targeting the PI3K pathway); and the MEK inhibitor trametinib (targeting the RAS/RAF/MEK pathway).